New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - lidocaine hydrochloride monohydrate 10 mg/ml;  ; methylprednisolone acetate 40 mg/ml - injection (depot) - 40 mg/ml - active: lidocaine hydrochloride monohydrate 10 mg/ml   methylprednisolone acetate 40 mg/ml - depo-medrol with lidocaine by intra-synovial of soft tissue administration (including periarticular and intrabursal) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: · synovitis of osteoarthritis · rheumatoid arthritis · acute gouty arthritis · epicondylitis · acute nonspecific tenosynovitis · post-traumatic osteoarthritis · acute and subacute bursitis

Canada - English - Health Canada

pfizer canada ulc - methylprednisolone (methylprednisolone sodium succinate) - kit - 1g - methylprednisolone (methylprednisolone sodium succinate) 1g - adrenals

Canada - English - Health Canada

pfizer canada ulc - methylprednisolone (methylprednisolone sodium succinate) - kit - 500mg - methylprednisolone (methylprednisolone sodium succinate) 500mg - adrenals

Canada - English - Health Canada

pfizer canada ulc - methylprednisolone (methylprednisolone sodium succinate) - kit - 40mg - methylprednisolone (methylprednisolone sodium succinate) 40mg - adrenals

Canada - English - Health Canada

pfizer canada ulc - methylprednisolone (methylprednisolone sodium succinate) - kit - 125mg - methylprednisolone (methylprednisolone sodium succinate) 125mg - adrenals

Canada - English - Health Canada

pfizer canada ulc - methylprednisolone (methylprednisolone sodium succinate) - kit - 500mg - methylprednisolone (methylprednisolone sodium succinate) 500mg - adrenals

Canada - English - Health Canada

pfizer canada ulc - methylprednisolone (methylprednisolone sodium succinate) - kit - 1g - methylprednisolone (methylprednisolone sodium succinate) 1g - adrenals

United States - English - NLM (National Library of Medicine)

greenstone llc - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - methylprednisolone tablets are indicated in the following conditions: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis bullous dermatitis herpetiformis severe erythema multiforme (stevens-johnson syndrome) severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loeffler's syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) hemolytic anemia erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. to tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. trichinosis with neurologic or myocardial involvement. systemic fungal infections and known hypersensitivity to components.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 40 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-medrol sterile aqueous suspension is indicated as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases : bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital ad

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 40 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-medrol sterile aqueous suspension is indicated as follows: allergic states : control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases : bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders : primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adr